The Bertelsmann-backed manufacturing software developer took its total funding past $110m with the close of the $77.3m round.

The Rabobank-backed accounting software and marketplace provider was valued at about $244m in an investment by Lugard Road Capital.

Legend Capital has returned to invest in the metabolic and immunological disease-focused biotechnology developer, having backed its series A round two years ago.

MIT’s cancer and infectious disease therapy spinout has added $40m to a round that will support the progression of its lead asset into the clinic.

Xfund is among the backers of a $17m round for ImmuneID, which has been set up to commercialise research from Harvard University and Johns Hopkins University.

The bicycle rental service, which was spun off by Didu Chuxing, is reportedly to close a $600m series B round alongside $400m in debt financing.

The Qilu Pharmaceutical-backed cancer, immune disorder and metabolic disease drug developer has closed a series B round led by Lilly Asia Ventures.

The Progressive-backed digital banking technology provider has now secured at least $482m in total, with Russell Westbrook Enterprises leading its latest round.

The Livzon-backed cancer and infectious disease therapy developer has added $40m to a round that will support the progression of its lead candidate toward clinical trials.

Telstra and Standard Chartered Ventures helped the cloud security software provider hike its overall funding to about $185m.